Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide y in patients with type 2 diabetes mellitus

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 4, 2011, Pages 401-420

  Katsiki, Niki ^a,b   Mikhailidis, Dimitri P ^b   Gotzamani Psarrakou, Anna ^a   Yovos, John G ^a   Karamitsos, Dimitrios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Adiponectin; ghrelin; insulin; leptin; neuropeptide Y; obesity; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EXENDIN 4; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; GHRELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LEPTIN; METFORMIN; NATEGLINIDE; NEUROPEPTIDE Y; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; RIMONABANT; SIMVASTATIN; SULFONYLUREA; UNINDEXED DRUG;

DIABETIC PATIENT; DRUG EFFECT; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ADIPONECTIN; DIABETES MELLITUS, TYPE 2; FEMALE; GHRELIN; HUMANS; HYPOGLYCEMIC AGENTS; LEPTIN; MALE; NEUROPEPTIDE Y;

EID: 79952667048     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.553609     Document Type: Review

References (281)

1. Russel-Jones D, Khan R. Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diab Obes Metab 2007;9:799-812 (Pubitemid 47555203)
2. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med 2007;15:231-5
3. Heller S. Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diab Res Clin Pract 2004;65S:S23-7 (Pubitemid 39094755)
4. Rigalleau V, Delafaye C, Baillet L, et al. Composition of insulin-induced body weight gain in diabetic patients: a body bio-impedance study. Diabetes Metab 1999;25:321-8 (Pubitemid 29505901)
5. United Kingdom Prospective Diabetes Study. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
6. Laville M, Andreelli F. Mechanisms for weight gain during blood glucose normalization. Diabetes Metab 2000;26(Suppl 3):42-5 (Pubitemid 30451516)
7. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 1999;42:406-12 (Pubitemid 29148398)
8. Carver C. Insulin treatment and the problem of weight gain in type 2 diabetes. Diabetes Educ 2006;32:910-17 (Pubitemid 44706818)
9. Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2001;2:282-6 (Pubitemid 32401521)
10. Yki-Jarvinen H, Ryysy L, Kauppila M, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:4037-43 (Pubitemid 27525508)
11. Schwartz MW, Porte D Jr. Diabetes, obesity and the brain. Science 2005;307:375-9
12. Schwartz MW, Niswender KD. Adiposity signalling and biological defence against weight gain: absence of protection or central hormone resistance? J Clin Endocrinol Metab 2004;89:5889-97 (Pubitemid 39628388)
13. Porte D Jr, Baskin DG, Schwartz MW. Insulin signalling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 2005;54:1264-76 (Pubitemid 40586653)
14. Stanley S, Wynne K, McGowan B, Bloom S. Hormonal regulation of food intake. Physiol Rev 2005;85:1131-58 (Pubitemid 41363743)
15. Havel PJ. Peripheral signals conveying metabolic information to the brain: short-term and long-term regulation of food intake and energy homeostasis. Exp Biol Med 2001;226:963-77
16. Ahima RS, Qi Y, Singhal NS. Adipokines that link obesity and diabetes to the hypothalamus. Prog Brain Res 2006;153:155-74 (Pubitemid 44107415)
17. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature 2000;404:661-71 (Pubitemid 30205071)
18. Morrison CD, Huypens P, Stewart LK, Gettys TW. Implications of cross-talk between leptin and insulin signaling during the development of diet induced obesity. Biochim Biophys Acta 2009;1792:409-16
19. Masuzaki H, Ogawa Y, Isse N, et al. Human obese gene expression. Adipocyte-specific expression and regional differences in the adipose tissue. Diabetes 1995;44:855-8
20. Jequier E. Leptin signalling, adiposity and energy balance. Ann NY Acad Sci 2002;967:379-88 (Pubitemid 34721923)
21. Niswender KD, Baskin DG, Schwartz MW. Insulin and its evolving partnership with leptin in the hypothalamic control of energy homeostasis. Trends Endocrinol Metab 2004;15:362-9 (Pubitemid 39223342)
22. Levin BE, Dunn-Meynell AA. Dysregulation of arcuate nucleus preproneuropeptide Y mRNA in diet-induced obese rats. Am J Physiol 1997;272(5 Pt 2):R1365-70
23. Scarpace PJ, Zhang Y. Leptin resistance: a predisposing factor for diet-inducedobesity. Am J Physiol Regul Integr Comp Physiol 2009;296:R493-500
24. Seufert J, Kieffer TJ, Leech CA, et al. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metab 1999;84:670-6 (Pubitemid 29075704)
25. Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes 2004;53(Suppl 1):S152-8 (Pubitemid 38168708)
26. Paraskevas KI, Liapis CD, Mikhailidis DP. Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. Curr Drug Targets 2006;7:761-71 (Pubitemid 43827272)
27. Hickey MS, Israel RG, Gardiner SN, et al. Gender differences in serum leptin levels in humans. Biochem Mol Med 1996;59:1-6 (Pubitemid 26346750)
28. Saad MF, Damani S, Gingerich RL, et al. Sexual dimorphism in plasma leptin concentration. J Clin Endocrinol Metab 1997;82:579-84 (Pubitemid 27068633)
29. Thomas T, Burguera B, Melton LJ III, et al. Relationship of serum leptin levels with body composition and sex steroid and insulin levels in men and women. Metabolism 2000;49:1278-84
30. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5 (Pubitemid 26033933)
31. Tatti P, Masselli L, Buonanno A, et al. Leptin levels in diabetic and nondiabetic subjects. Endocrine 2001;15:305-8 (Pubitemid 33096235)
32. Marita AR, Sarkar JA, Rane S. Type 2 diabetes in non-obese Indian subjects is associated with reduced leptin levels: study from Mumbai, Western India. Mol Cell Biochem 2005;275:143-51 (Pubitemid 41030990)
33. Lele RD, Joshi SR, Gupte A. Association of adipocytokines (leptin, adiponectin, TNF-alpha), insulin and proinsulin with diabetes- the Mumbai Obesity Project [MOP]. J Assoc Physicians India 2006;54:689-96 (Pubitemid 44371915)
34. Panarotto D, Ardilouze JL, Tessier D, Maheux P. The degree of hyperinsulinemia and impaired glucose tolerance predicts plasma leptin concentrations in women only: a new exploratory paradigm. Metabolism 2000;49:1055-62 (Pubitemid 30641445)
35. Haffner SM, Stern MP, Miettinen H, et al. Leptin concentrations in diabetic and nondiabetic Mexican-Americans. Diabetes 1996;45:822-4 (Pubitemid 26168584)
36. Uckaya G, Ozata M, Bayraktar Z, et al. Is leptin associated with diabetic retinopathy? Diabetes Care 2000;23:371-6
37. Widjaja A, Stratton IM, Horn R, et al. UKPDS 20: plasma leptin, obesity and plasma insulin in type 2 diabetic subjects. J Clin Endocrinol Metab 1997;82:654-7 (Pubitemid 27068646)
38. Huang CC, Lin JD, Chang HY. The influence of long-term different diabetic therapies on plasma leptin in type 2 diabetic subjects. Endocr J 2001;48:377-83
39. Milewicz A, Mikulski E, Bidzinska B. Plasma insulin, cholecystokinin, galanin, neuropeptide Y and leptin levels in obese women with and without type 2 diabetes mellitus. Int J Obes Relat Metab Disord 2000;24(Suppl 2):S152-3 (Pubitemid 30461980)
40. Hattori A, Uemura K, Miura H, et al. Gender-related difference in relationship between insulin resistance and serum leptin level in Japanese type 2 diabetic and non-diabetic subjects. Endocr J 2000;47:615-21
41. Okumura T, Taniguchi A, Nagasaka S, et al. Relationship of regional adiposity to serum leptin level in nonobese Japanese type 2 diabetic male patients. Diabetes Metab 2003;29:15-18 (Pubitemid 36362611)
42. Eriksson J, Valle T, Lindstrom J, et al. Leptin concentrations and their relation to body fat distribution and weight loss - a prospective study in individuals with impaired glucose tolerance. DPS-study group. Horm Metab Res 1999;31:616-19
43. Williams KV, Mullen M, Lang W, et al. Weight loss and leptin changes in individuals with type 2 diabetes. Obes Res 1999;7:155-63 (Pubitemid 129710573)
44. Ozkan Y, Aydin S, Donder E, et al. Effect of orlistat on the total ghrelin and leptin levels in obese patients. J Physiol Biochem 2009;65:215-23
45. Whitson BA, Leslie DB, Kellogg TA, et al. Adipokine response in diabetics and nondiabetics following the Roux-en-Y gastric bypass: a preliminary study.J Surg Res 2007;142:295-300 (Pubitemid 47418830)
46. Faraj M, Havel PJ, Phelis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003;88:1594-602 (Pubitemid 36623375)
47. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003;26:2442-50 (Pubitemid 36993340)
48. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-6 (Pubitemid 32756432)
49. Dridi S, Taouis M. Adiponectin and energy homeostasis: consensus and controversy. J Nutr Biochem 2009;20:831-9
50. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-95 (Pubitemid 35373562)
51. Guillod-Maximin E, Roy AF, Vacher CM, et al. Adiponectin receptors are expressed in hypothalamus and colocalized with propiomelanocortin and neuropeptide Y in rodent arcuate neurons. J Endocrinol 2009;200:93-105
52. Ahima RS, Qi Y, Singhal NS, et al. Brain adipocytokines action and metabolic regulation. Diabetes 2006;55(Suppl 2):S145-54 (Pubitemid 44927045)
53. Qi Y, Takahashi N, Hileman SM, et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004;10:524-9 (Pubitemid 38667912)
54. Nishizawa H, Shimomura I, Kishida K, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002;51:2734-41 (Pubitemid 34970926)
55. Zhang J, Holt RI, Wild SH, et al. Plasma adiponectin concentrations are independently predicted by fat insulin sensitivity in women and by muscle insulin sensitivity in men. Diabetes Care 2005;28:755-6 (Pubitemid 40315348)
56. Putz DM, Goldner WS, Bar RS, et al. Adiponectin and C-reactive protein in obesity, type 2 diabetes and monodrug therapy. Metabolism 2004;53:1454-61 (Pubitemid 39410386)
57. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83 (Pubitemid 29299050)
58. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9 (Pubitemid 30353893)
59. Ezenwaka CE, Kalloo R. Caribbean female patients with type 2 diabetes mellitus have lower serum levels of adiponectin than nondiabetic subjects. Neth J Med 2005;63:64-9 (Pubitemid 40347736)
60. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5 (Pubitemid 32472900)
61. Sharma PK, Bhansali A, Sialy R, et al. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2006;65:722-8 (Pubitemid 44772351)
62. Anderlova K, Dolezalova R, Housova J, et al. Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. Physiol Res 2007;56:579-86
63. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009;302:179-88
64. Han SH, Sakuma I, Shin EK, Koh KK. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis 2009;52:126-40
65. Schulze MB, Shai I, Rimm EB, et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005;54:534-9
66. Mantzoros CS, Li T, Manson JE, et al. Circulating adiponectin levels are associated with better glycemic control, more favourable lipid profile and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4542-8 (Pubitemid 41159340)
67. Schulze MB, Rimm EB, Shai I, et al. Relationship between adiponectin and glycemic control, blood lipids and inflammatory markers in men with type 2 diabetes. Diabetes Care 2004;27:1680-7 (Pubitemid 38857444)
68. Hung WC, Wang CP, Lu LF, et al. Circulating adiponectin level is associated with major adverse cardiovascular events in type 2 diabetic patients with coronary artery disease. Endocr J 2010;57:793-802
69. Wannamethee SG, Welsh P, Whincup PH, et al. High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association? Eur J Cardiovasc Prev Rehabil 2010: published online 25 May 2011, doi: 10.1097/HJR.0b013e32833b09d9
70. Fujita H, Morii T, Koshimura J, et al. Possible relationship between adiponectin and renal tubular injury in diabetic nephropathy. Endocr J 2006;53:745-52 (Pubitemid 46045119)
71. Ouchi N, Kihara S, Funahashi T, et al. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003;14:561-6 (Pubitemid 41623184)
72. Kobayashi H, Ouchi N, Kihara S, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004;94:e27-31
73. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000;407:908-13
74. Dezaki K, Sone H, Yada T. Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol Ther 2008;118:239-49
75. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992-5 (Pubitemid 33152655)
76. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001;409:194-8 (Pubitemid 32144284)
77. Kamegai J, Tamura H, Shimizu T, et al. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes 2001;50:2438-43 (Pubitemid 33642759)
78. Lawrence CB, Snape AC, Baudoin FM, Luckman SM. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centres. Endocrinology 2002;143:155-62 (Pubitemid 34056414)
79. Murata M, Okimura Y, Iida K, et al. Ghrelin modulates the downstream molecules of insulin signalling in hepatoma cells. J Biol Chem 2002;277:5667-74 (Pubitemid 34968622)
80. Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001;86:5083-6 (Pubitemid 33020569)
81. Date Y, Nakazato M, Hashiguchi S, et al. Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes 2002;51:124-9 (Pubitemid 34517988)
82. Greenman Y, Golani N, Gilad S, et al. Ghrelin secretion is modulated in a nutrient- and gender-specific manner. Clin Endocrinol (Oxf) 2004;60:382-8 (Pubitemid 38297130)
83. Greenman Y, Rouach V, Limor R, et al. Testosterone is a strong correlate of ghrelin levels in men and postmenopausal women. Neuroendocrinology 2009;89:79-85
84. Makovey J, Naganathan V, Seibel M, Sambrook P. Gender differences in plasma ghrelin and its relations to body composition and bone-an opposite-sex twin study. Clin Endocrinol (Oxf) 2007;66:530-7 (Pubitemid 46434935)
85. Purnell JQ, Weigle DS, Breen P, Cummings DE. Ghrelin levels correlate with insulin levels, insulin resistance and high-density lipoprotein cholesterol, but not with gender, menopausal status or cortisol levels in humans. J Clin Endocrinol Metab 2003;88:5747-52 (Pubitemid 38033045)
86. Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50:707-9 (Pubitemid 32242624)
87. Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002;87:240-4 (Pubitemid 34084697)
88. Katsuki A, Urakawa H, Gabazza EC, et al. Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia ands insulin resistance in patients with type 2 diabetes mellitus. Eur J Endocrinol 2004;151:573-7 (Pubitemid 39562512)
89. Couce ME, Cottam D, Esplen J, et al. Potential role of hypothalamic ghrelin in the pathogenesis of human obesity. J Endocrinol Invest 2006;29:599-605 (Pubitemid 44446269)
90. Ueno H, Shiiya T, Mizuta M, et al. Plasma ghrelin concentrations in different clinical stages of diabetic complications and glycemic control in Japanese diabetics. Endocr J 2007;54:895-902 (Pubitemid 351346772)
91. Morinigo R, Casamitjana R, Moize V, et al. Short-term effects of gastric bypass surgery on circulating ghrelin levels. Obes Res 2004;12:1108-16 (Pubitemid 41132490)
92. Fruhbeck G, Rotellar F, Hernandez-Lizoain JL, et al. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg 2004;14:1208-15 (Pubitemid 39458595)
93. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-30 (Pubitemid 34755670)
94. Beaumont NJ, Skinner VO, Tan TMM, et al. Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem 2003;278:8877-80 (Pubitemid 36800362)
95. De Vriese C, Hacquebard M, Gregoire F, et al. Ghrelin interacts with human plasma lipoproteins. Endocrinology 2007;148:2355-62 (Pubitemid 46997038)
96. Ariyasu H, Takaya K, Hosoda H, et al. Delayed short-term secretory regulation of ghrelin in obese animals: evidenced by a specific RIA for the active form of ghrelin. Endocrinology 2002;143:3341-50 (Pubitemid 34925708)
97. Murakami N, Hayashida T, Kuroiwa T, et al. Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats. J Endocrinol 2002;174:283-8 (Pubitemid 34965767)
98. Chronwall BM, Zukowska Z. Neuropeptide Y, ubiquitous and elusive. Peptides 2004;25:359-63
99. Kos K, Harte AL, James S, et al. Secretion of neuropeptide Y in human adipose tissue and its role in maintenance of adipose tissue mass. Am J Physiol Endocrinol Metab 2007;293:E1335-40 (Pubitemid 350106602)
100. Stanic D, Brumovsky P, Fetissov S, et al. Characterization of neuropeptide Y2 receptor protein expression in the mouse brain. I. Distribution in cell bodies and nerve terminals. J Comp Neurol 2006;499:357-90 (Pubitemid 44571934)
101. Fetissov S, Byrne LC, Hassani H, et al. Characterization of neuropeptide Y Y2 and Y5 receptor expression in the mouse hypothalamus. J Comp Neurol 2004;470:256-65 (Pubitemid 38160680)
102. Ukkola O, Kesaniemi YA. Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects. Eur J Clin Nutr 2007;61:1102-5 (Pubitemid 47386596)
103. Nordman S, Ding B, Ostenson CG, et al. Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired glucose tolerance and type 2 diabetes in Swedish men. Exp Clin Endocrinol Diabetes 2005;113:282-7 (Pubitemid 40868184)
104. Niskanen L, Karvonen MK, Valve R, et al. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in the elderly patient with type 2 diabetes and control subjects. J Clin Endocrinol Metab 2000;85:2266-9 (Pubitemid 32269253)
105. Niskanen L, Voutilainen-Kaunisto R, Terasvirta M, et al. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with retinopathy in type 2 diabetes. Exp Clin Endocrinol Diabetes 2000;108:235-6 (Pubitemid 30315904)
106. Satoh C, Satoh F, Takahashi K, et al. Elevated plasma immunoreactive neuropeptide Y concentrations and its increased urinary excretion in patients with advanced diabetic nephropathy. Endocr J 1999;46:139-46 (Pubitemid 29197758)
107. Carstensen E, Sampson MJ, Savage MW, et al. Lack of relationship between sympathetic nervous system activity, measured by two circulating markers, and blood pressure in diabetic and nondiabetic subjects. J Diab Comp 1998;12:140-6 (Pubitemid 28241438)
108. Stafford JM, Yu F, Printz R, et al. Central nervous system neuropeptide Y signalling modulates VLDL triglyceride secretion. Diabetes 2008;57:1482-90
109. Bruning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000;289:2122-5
110. Vollenweider P, Randin D, Tappy L, et al. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Endocrinol Metab 1994;93:2365-71 (Pubitemid 24177147)
111. Air EL, Strowski MZ, Benoit SC, et al. Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity. Nat Med 2002;8:179-83 (Pubitemid 34155130)
112. Kolaczynski JW, Nyce MR, Considine RV, et al. Acute and chronic effects of insulin on leptin production in humans: studies in vivo and in vitro. Diabetes 1996;45:699-701 (Pubitemid 26142812)
113. Halleux CM, Takahashi M, Delporte ML, et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 2001;288:1102-7 (Pubitemid 33131713)
114. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-9
115. Fasshauer M, Klein J, Neumman S, et al. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002;290:1084-9 (Pubitemid 34687474)
116. Schwartz W, Sipols AJ, Marks JL, et al. Inhibition of hypothalamic neuropeptide Y gene expression by insulin. Endocrinology 1992;130:3608-16
117. Malmstrom R, Taskinen MR, Karonen S, Yki-Jarvinen H. Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM. Diabetologia 1996;39:993-6 (Pubitemid 26249121)
118. Aas AM, Hanssen KF, Berg JP, et al. Insulin-stimulated increase in serum leptin levels precedes and correlates with weight gain during insulin therapy in type 2 diabetes. J Clin Endocrinol Metab 2009;94:2900-6
119. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weight gain in type 2 diabetes mellitus. Diabetes Obes Metab 2007;9:386-93 (Pubitemid 46502059)
120. Aas AM, Seljeflot I, Torjesen PA, et al. Blood glucose lowering by means of lifestyle intervention has different effects on adipokines as compared with insulin treatment in subjects with type 2 diabetes. Diabetologia 2006;49:872-80
121. Carey PE, Stewart MW, Ashworth L, Taylor R. Effect of insulin therapy onplasma leptin and body weight in patient with type 2 diabetes. Horm Metab Res 2003;35:372-6 (Pubitemid 37102683)
122. Miyashita Y, Nishimura R, Nemoto M, et al. Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure. Cardiovasc Diabetol 2008;7:16
123. Anderwald C, Brabant G, Bernroider E, et al. Insulin-dependent modulation ofplasma ghrelin and leptin concentrations is less pronounced in type 2 diabetic patients. Diabetes 2003;52:1792-8 (Pubitemid 36792472)
124. Sivitz WI, Wayson SM, Bayless ML, et al. Leptin and body fat in type 2 diabetes and monodrug therapy. J Clin Endocrinol Metab 2003;88:1543-53 (Pubitemid 36623368)
125. Adamia N, Virsaladze D, Charkviani N, et al. Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes. Georgian Med News 2007;145:52-5
126. Derosa G, Salvadeo SA, DAngelo A, et al. Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. Arch Med Res 2008;39:412-19
127. Nagasaka S, Taniguchi A, Aiso Y, et al. Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes. Diabetes Care 2003;26:2215-16
128. Doogue MP, Begg EJ, Moore MP, et al. Metformin increases plasma ghrelin in type 2 diabetes. Br J Clin Pharmacol 2009;68:875-82
129. Kusaka I, Nagasaka S, Horie H, Ishibashi S. Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability? Diabetes Obes Metab 2008;10:1039-46
130. Kiyici S, Ersoy C, Oz Gul O, et al. Total and acylated ghrelin levels in type 2 diabetic patients: similar levels observed after treatment with metformin, pioglitazone or diet therapy. Exp Clin Endocrinol Diabetes 2009;117:386-90
131. Kadoglou NP, Tsanikidis H, Kapelouzou A, et al. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism 2010;59:373-9
132. Phillips SA, Ciaraldi TP, Kong APS, et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003;52:667-74 (Pubitemid 36323573)
133. Araki T, Emoto M, Konishi T, et al. Glimepiride increases high-density lipoprotein via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism 2009;58:143-8
134. Tsunekawa T, Hayashi T, Suzuki Y, et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care 2003;26:285-9 (Pubitemid 36929044)
135. Koshiba K, Nomura M, Nakaya Y, Ito S. Efficacy of glimepiride on insulin resistance, adipocytokines and atherosclerosis. J Med Invest 2006;53:87-94
136. Drzewoski J, Zurawska-Klis M. Effect of gliclazide modified release on adiponectin, interleukin-6 and tumor necrosis factor-alpha plasma levels in individuals with type 2 diabetes mellitus. Curr Med Res Opin 2006;22:1921-6 (Pubitemid 44663396)
137. Chou HS, Palmer JP, Jones AR, et al. Initial treatemtn with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. Diabetes Obes Metab 2008;10:626-37 (Pubitemid 352044292)
138. Mori Y, Itoh Y, Obata T, Tajima N. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes. Endocrine 2006;29:143-8 (Pubitemid 43780357)
139. Haffner SM, Hanefeld M, Fischer S, et al. Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM. Diabetes Care 1997;20:1430-4 (Pubitemid 27366820)
140. Bhattacharya SK, Madan M, Mahajan P, et al. Relationship between plasma leptin and plasma insulin levels in type-2 diabetic patients before and after treatment with glibenclamide and glimepiride. Indian J Physiol Pharmacol 2008;52:43-52 (Pubitemid 351820259)
141. Ozata M, Gungor D, Turan M, et al. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects. J Clin Endocrinol Metab 2001;86:3659-64 (Pubitemid 32755958)
142. Guler S, Cakir B, Demirbas B, et al. Leptin concentrations are related to glycaemic control, but do not change with short-term oral antidiabetic therapy in female patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000;2:313-16 (Pubitemid 33072200)
143. Ochiai H, Ooka H, Shida C, et al. Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes. Endocr J 2008;55:549-56 (Pubitemid 351949751)
144. Kim HJ, Kim SK, Shim WS, et al. Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008;81:42-9
145. Oz O, Tuncel E, Eryilmaz S, et al. Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones. Endocrine 2008;33:101-5
146. Miyazaki Y, Mahankali A, Wajcberg E, et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:4312-19 (Pubitemid 39244431)
147. Chu CS, Lee KT, Lee MY, et al. Effects of rosiglitazone alone and in combination with atorvastatin on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 2006;97:646-50
148. Von Bibra H, Diamant M, Scheffer PG, et al. Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. Diab Vasc Dis Res 2008;5:310-18
149. Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferators- activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25:376-80
150. Tan GD, Debard C, Funahashi T, et al. Changes in adiponectin receptor
151. Kang ES, Park SY, Kim HJ, et al. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care 2005;28:1139-44
152. Bajaj M, Suraamornkul S, Hardies LJ, et al. Effects of peroxisome proliferators-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose andn lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007;50:1723-31 (Pubitemid 47036647)
153. Tsuchiya K, Akaza I, Yoshimoto T, Hirata Y. Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in type 2 diabetes. Endocr J 2009;56:691-8
154. Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 2008;10:1204-11
155. Martens FM, Visseren FL, de Koning EJ, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 2005;46:773-8 (Pubitemid 44378249)
156. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003;26:2493-9 (Pubitemid 37055444)
157. Dorkhan M, Frid A, Groop L. Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add-insulin glargine or pioglitazone? Diabetes Res Clin Pract 2008;82:340-5
158. Shimizu H, Oh-I S, Tsuchiya T, et al. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in type 2 diabetic patients: a randomized study. Diabet Med 2006;23:253-7
159. Aso Y, Hara K, Ozeki N, et al. Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes. Diabetes Res Clin Pract 2009;85:147-52
160. Igarashi M, Hirata A, Yamaguchi H, et al. Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients. J Atheroscler Thromb 2008;15:34-40
161. Hohberg C, Pfutzner A, Forst T, et al. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study. Diabetes Obes Metab 2009;11:464-71
162. Derosa G, Fogari E, Cicero AF, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res 2007;30:387-94 (Pubitemid 46958888)
163. Hiramatsu S, Tajiri Y, Karashima T. Lower plasma adiponectin concentration predicts the efficacy of pioglitazone in diabetic patients. Diabetes Obes Metab 2004;6:231-3 (Pubitemid 38559704)
164. Otto C, Otto B, Goke B, et al. Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels. J Endocrinol Invest 2006;29:231-6
165. Martin CK, Gupta AK, Smith SR, et al. Effect of pioglitazone on energy intake and ghrelin in diabetic patients. Diabetes Care 2010;33:742-4
166. Rudovich N, Mohling M, Otto B, et al. Effect of meglitinides on postprandial ghrelin secretion pattern in type 2 diabetes mellitus. Diabetes Technol Ther 2010;12:57-64
167. Iwase M, Iino K, Doi Y, et al. Nateglinide may increase high-molecular weight adiponectin in type 2 diabetic patients with hypoadiponectinemia. Diabetes Res Clin Pract 2008;82:e19-22
168. Kim Chung Ie T, Hosaka T, Yoshida M, et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun 2009;390:613-18
169. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. Expert Opin Pharmacother 2008;9:1705-20
170. Derosa G, Maffioli P, Salvadeo SA, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010;59:887-95
171. Delles C, Raff U, Mimran A, et al. Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes. Am J Hypertens 2008;21:1330-6
172. Fernandez M, Triplitt C, Wajcberg E, et al. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. Diabetes Care 2008;31:121-7
173. Koh KK, Quon MJ, Han SH, et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005;45:1088-93 (Pubitemid 40770310)
174. Hermann TS, Li W, Dominguez H, et al. Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:1001-8 (Pubitemid 43357772)
175. Huang SS, Wu TC, Lin SJ, Chen JW. Combination of an ACE inhibitor and indapamide improves blood pressure control, but attenuates the beneficial effects of ACE inhibition on plasma adiponectin in patients with essential hypertension. Circ J 2009;73:2282-7
176. Cassis LA, English VL, Bharadwaj K, Boustany CM. Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. Endocrinology 2004;145:169-74 (Pubitemid 38094512)
177. Lewandowski J, Abramczyk P, Dobosiewicz A, et al. The effect of enalapril and telmisartan on clinical and biochemical indices of sympathetic activity in hypertensive patients. Clin Exp Hypertens 2008;30:423-32 (Pubitemid 352009299)
178. Fuke Y, Fujita T, Satomura A, et al. Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment. Diabetes Technol Ther 2010;12:393-8
179. Mori Y, Itoh Y, Tajima N. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther 2007;24:146-53 (Pubitemid 46700873)
180. Nomura S, Shouzu A, Omoto S, et al. Effect of valsartan on monocyte/ endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006;117:385-92 (Pubitemid 43197489)
181. Lee JM, Kim JH, Son HS, et al. Valsartan increases circulatingadiponectin levels without changing HOMA-IR in patients with type 2 diabetes mellitus and hypertension. J Int Med Res 2010;38:234-41
182. Usui I, Fujisaka S, Yamazaki K, et al. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 2007;77:210-14 (Pubitemid 46670421)
183. Ozaki N, Nomura Y, Sobajima H, et al. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. Eur J Intern Med 2010;21:236-9
184. Komiya N, Hirose H, Saisho Y, et al. Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension. Int Heart J 2008;49:681-9
185. Brody R, Peleg E, Grossman E, Sharabi Y. Production and secretion of adiponectin from 3T3-L1 adipocytes: comparison of antihypertensive. Am J Hypertens 2009;22:1126-9
186. Derosa G, Fogari E, DAngelo A, et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007;32:261-8 (Pubitemid 46699517)
187. Derosa G, Cicero AF, DAngelo A, et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res 2006;29:849-56 (Pubitemid 46062116)
188. Negro R, Hassan H. The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. J Renin Angiotensin Aldosterone Syst 2006;7:243-6 (Pubitemid 46380776)
189. Guo LL, Pan Y, Jin HM. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant 2009;24:1876-83
190. Park H, Hasegawa G, Obayashi H, et al. Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension. Clin Chim Acta 2006;374:129-34 (Pubitemid 44572247)
191. Aubert G, Burnier M, Dulloo A, et al. Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gain. Metabolism 2010;59:25-32
192. Nomura S, Inami N, Kimura Y, et al. Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens 2007;21:38-44 (Pubitemid 44929342)
193. Ersoy C, Imamoglu S, Budak F, et al. Effect of amlodipine on insulin resistance & tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients. Indian J Med Res 2004;120:481-8 (Pubitemid 40044920)
194. Kovacic D, Marinsek M, Gobec L, et al. Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin Res Cardiol 2008;97:24-31
195. Yamaji M, Tsutamoto T, Tanaka T, et al. Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure. Circ J 2009;73:1067-73
196. Koh KK, Quon MJ, Han SW, et al. Distinct vascular and metabolic effects of different classes of antihypertensive drugs. Int J Cardiol 2010;140:73-81
197. Malminiemi K. Long-term celiprolol therapy lowers fasting plasma leptin levels. Celiprolol Multicenter Study Group. Cardiovasc Drugs Ther 2000;14:67-75 (Pubitemid 30139224)
198. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006;24:591-6 (Pubitemid 43261924)
199. Yilmaz MI, Sonmez A, Caglar K, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology 2007;12:147-53 (Pubitemid 46426854)
200. Matsumoto S, Takebayashi K, Aso Y. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism 2006;55:1645-52 (Pubitemid 44827131)
201. Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract 2006;60:621-9
202. Ueshiba H, Miyachi Y. Effect of doxazosin on insulin resistance in hypertensive patients with obesity. Horm Metab Res 2003;35:532-6 (Pubitemid 37260417)
203. Ebinc H, Ozkurt ZN, Ebinc FA, et al. Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women. J Int Med Res 2008;36:80-7 (Pubitemid 351255973)
204. Skoczylas A, Adamczak M, Chudek J, Wiecek A. Cilazapril increases plasma ghrelin concentration in obese patients with arterial hypertension. Endokrynol Pol 2010;61:21-7
205. Perelas A, Tsoulkani A, Perrea D. Effects of lipid-lowering drugs on adiponectin. Curr Vasc Pharmacol 2010;8:836-48
206. Chu CH, Lee JK, Lam HC, et al. Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic type 2 diabetes. J Endocrinol Invest 2008;31:42-7
207. Otto C, Otto B, Frost RJA, et al. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetol 2007;44:65-8 (Pubitemid 46835447)
208. Von Eynatten M, Schneider JG, Hadziselimovic S, et al. Adipocytokines as a novel target for the anti-infalmmatory effect of atorvastatin in patients with type 2 diabetes. Diabetes Care 2005;28:754-5 (Pubitemid 40315347)
209. Von Eynatten M, Liu D, Bluemm A, et al. Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes. Clin Endocrinol (Oxf) 2009;71:27-32
210. Van Hoek M, van Tol A, van Vark-van der Zee, et al. Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes. Curr Med Res Opin 2009;25:93-101
211. Bulcao C, Guiffrida FM, Ribeiro-Filho FF, Ferreira SR. Are thebeneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity? Braz J Med Biol Res 2007;40:229-35 (Pubitemid 46237855)
212. Bellia A, Rizza S, Galli A, et al. Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. Atherosclerosis 2010;210:199-201
213. Hu Y, Tong G, Xu W, et al. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. Diab Vasc Dis Res 2009;6:262-8
214. Takebayashi K, Suetsugu M, Matsumoto S, et al. Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. South Med J 2009;102:361-8
215. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62 (Pubitemid 32105973)
216. Takagi T, Matsuda M, Abe M, et al. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008;196:114-21
217. Sugiyama S, Fukushima H, Kugiyama K, et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007;194:e43-51 (Pubitemid 47513070)
218. Nomura S, Inami N, Shouzu A, et al. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets 2009;20:16-22
219. Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS. Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol 2010;8:612-31
220. Katsiki N, Tziomalos K, Chatzizisis Y, et al. Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental? Atherosclerosis 2010;211:9-14
221. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Lipid-lowering agents and new onset diabetes-mellitus. Expert Opin Pharmacother 2010;11:1965-70
222. Damci T, Tatliagac S, Osar Z, Ilkova H. Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. Eur J Intern Med 2003;14:357-60 (Pubitemid 40090259)
223. Ogawa S, Takeuchi K, Sugimura K, et al. Bezafibrate reduces blood glucose in type 2 diabetes mellitus. Metabolism 2000;49:331-4 (Pubitemid 30146563)
224. Yin WH, Jen HL, Chen JW, et al. Differential effects of peroxisome proliferators-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. Diabetes Metab 2006;32:229-35 (Pubitemid 43966746)
225. Banks WA, Coon AB, Robinson SM, et al. Triglycerides induce leptin resistance at the blood-brain-barrier. Diabetes 2004;53:1253-60 (Pubitemid 38569011)
226. Banks WA, Burney BO, Robinson SM. Effects of triglycerides, obesity, and starvation on ghrelin transport across the blood-brain-barrier. Peptides 2008;29:2061-5
227. Gouni-Berthold I, Berthold HK, Chamberland JP, et al. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol (Oxf) 2008;68:536-41 (Pubitemid 351388705)
228. Florentin M, Liberopoulos EN, Tellis CC, et al. Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study. Angiology 2010;61:365-71
229. Westphal S, Borucki K, Taneva E, et al. Extended-release niacin raises adiponectin and leptin. Atherosclerosis 2007;193:361-5 (Pubitemid 47058098)
230. Westphal S, Borucki K, Taneva E, et al. Adipokines and treatment with niacin. Metabolism 2006;55:1283-5 (Pubitemid 44353552)
231. Plaisance EP, Grandjean PW, Brunson BL, Judd RL. Increased total and high-molecular weight adiponectin after extended-release niacin. Metabolism 2008;57:404-9 (Pubitemid 351178732)
232. Linke A, Sonnabend M, Fasshauer M, et al. Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis 2009;205:207-13
233. Worm D, Vinten J, Vaag A, et al. The nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in type 2 diabetic patients. Eur J Endocrinol 2000;143:389-95
234. Tziomalos K, Athyros VG, Mikhailidis DP. Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009;5:16-17
235. Dziedzic B, Szemraj J, Bartkowiak J, Walczewska A. Various dietary fats differentially change the gene expression of neuropeptides involved in body weight regulation in rats. J Neuroendocrinol 2007;19:364-73 (Pubitemid 46547160)
236. Huang XF, Xin X, McLennan P, Storlien L. Role of fat amount and type in ameliorating diet-induced obesity: insights at the level of hypothalamic arcuate nucleus leptin receptor, neuropeptide Y and pro-opiomelanocortin mRNA expression. Diabetes Obes Metab 2004;6:35-44 (Pubitemid 38159727)
237. Wang H, Storlien LH, Huang XF. Effects of dietary fat types on body fatness, leptin and ARC leptin receptor, NPY and AgRP mRNA expression. Am Physiol Endocrinol Metab 2002;282:E1352-9 (Pubitemid 34654705)
238. Kopecky J, Rossmeisi M, Flachs P, et al. n-3 PUFA: bioavailability and modulation of adipose tissue. Proc Nutr Soc 2009;68:361-9
239. Banga A, Unal R, Tripathi P, et al. Adiponectin translation is increased by the PPARgamma agonists pioglitazone and w-3 fatty acids. Am J Physiol Endocrinol Metab 2009;296:E480-9
240. Kondo K, Morino K, Nishio Y, et al. Effects of a fish-based diet on the serum adiponectin concentration in young, non-obese, healthy Japanese subjects. J Atheroscler Thromb 2010;17:628-37
241. Tsitouras PD, Gucciardo F, Salbe AD, et al. High omega-3 fat intake improves insulin sensitivity and reduces CRP and IL6, but does not affect other endocrineaxes in healthy older adults. Horm Metab Res 2008;40:199-205 (Pubitemid 351690524)
242. Kratz M, Swarbrick MM, Callahan HS, et al. Effect of dietary n-3 polyunsaturated fatty acids on plasma total and high-molecular-weight adiponectin concentrations in overweight to moderately obese men and women. Am J Clin Nutr 2008;87:347-53 (Pubitemid 351226070)
243. Micallef MA, Garg ML. Anti-inflammatory and cardioprotective effects of n-3 polyunsaturated fatty acids and plant sterols in hyperlipidemic individuals. Atherosclerosis 2009;204:476-82
244. Patel JV, Lee KW, Tomson J, et al. Effects of omega-3 polyunsaturated fatty acids on metabolically active hormones in patients post-myocardial infarction. Int J Cardiol 2007;115:42-5 (Pubitemid 44856752)
245. Mostad IL, Bjerve KS, Basu S, et al. Addition of n-3 fatty acids to a 4-hour lipid infusion does not affect insulin sensitivity, insulin secretion, or markers of oxidative stress in subjects with type 2 diabetes mellitus. Metabolism 2009;58:1753-61
246. Sneddon AA, Tsofliou F, Fyfe CL, et al. Effect of a conjugated linoleic acid and w-3 fatty acid mixture on body composition and adiponectin. Obesity 2008;16:1019-24 (Pubitemid 351620483)
247. Tziomalos K, Dimitroula HV, Katsiki N, et al. Effects of lifestyle measures, antiobesity agents and bariatric surgery on serological markers of inflammation in obese patients. Mediators Inflamm 2010;2010:364957
248. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005;21:457-68
249. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005;31:15-22 (Pubitemid 40327588)
250. Hsieh CJ, Wang PW, Liu RT, et al. Orlistat for obesity: benefits beyond weight loss. Diabetes Res Clin Pract 2005;67:78-83
251. Valsamakis G, McTernan PG, Chetty R, et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favourable changes in serum adipocytokines. Metabolism 2004;53:430-4 (Pubitemid 38419183)
252. Madsen EL, Rissanen A, Bruun JM, et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008;158:179-87 (Pubitemid 351298534)
253. Derosa G, Maffioli P, Salvadeo SA, et al. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. Expert Opin Pharmacother 2010;11:1971-82
254. Dimitrov D, Bohchelian HM, Koeva L. Effect of orlistat on plasma leptin levels and risk factors for the metabolic syndrome. Metab Syndr Relat Disord 2005;3:122-9 (Pubitemid 41269270)
255. Dixon AN, Valsamakis G, Hanif MW, et al. Effect of the orlistat on serum endotoxin lipopolysaccharide and adipocytokines in South Asian individuals with impaired glucose tolerance. Int J Clin Pract 2008;62:1124-9 (Pubitemid 351793604)
256. Derosa G, Maffioli P, Salvadeo SA, et al. Effects of combination of sibutramine and l-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. Metabolism 2010: published online 27 April 2010, doi:10.1016/j. metabol.2010.03.010
257. Hung YJ, Chen YC, Pei D, et al. Sibutramine improves insulin sensitivity withourt alteration of serum adiponectin in obese subjects with type 2 diabetes. Diabet Med 2005;22:1024-30 (Pubitemid 41025999)
258. Erondu N, Addy C, Lu K, et al. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. Obesity 2007;15:2027-42 (Pubitemid 47402235)
259. Elbatamy HS, Netherton SJ, Ovens JD, et al. Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases. Eur J Pharmacol 2007;558:7-13 (Pubitemid 46328874)
260. Corsonello A, Malara A, De Domenico D, et al. Identifying pathways involved in leptin-dependent aggregation of human platelets. Int J Obes Relat Metab Disord 2004;28:979-84 (Pubitemid 38998702)
261. Restituto P, Colina I, Varo JJ, Varo N. Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome. Am J Physiol Endocrinol Metab 2010;298:E1072-7
262. Myers AK, Torres Duarte AP, Zukowska-Grojec Z. Immunoreactive neuropeptide Y (NPY) in plasma and platelets of rat and mouse strains and human volunteers. Regul Pept 1993;47:239-45
263. Mohling M, Freudenberg M, Bobbert T, et al. Acetylsalicylic acid improves lipid-induced insulin resistance in healthy men. J Clin Endocrinol Metab 2006;91:964-7 (Pubitemid 43357766)
264. Takahashi S, Ushida M, Komine R, et al. Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res 2007;119:517-24 (Pubitemid 46149893)
265. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2008;1:CD003748
266. Hsieh CJ, Wang PW. Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease. Circ J 2009;73:948-54
267. Wallaschofski H, Lohmann T, Hild E, et al. Enhanced platelet activation by prolactin in patients with ischemic stroke. Thromb Haemost 2006;96:38-44 (Pubitemid 44160869)
268. Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006;7:211-28
269. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XEnical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61 (Pubitemid 38196725)
270. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003 (Pubitemid 34286536)
271. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;363:2022-31 (Pubitemid 38781102)
272. Athyros VG, Tziomalos K, Karagiannis A, et al. Should adipokines be considered in the choice of treatment of obesity-related health problems? Curr Drug Targets 2010;11:122-35
273. Filippatos TD, Randeva HS, Derdemezis CS, et al. Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol 2010;8:12-28
274. Gomez R, Lago F, Gomez-Reino JJ, Gualillo O. Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin. Expert Opin Ther Targets 2009;13:583-91
275. Kalra SP. Disruption in the leptin-NPY link underlies the pandemic of diabetes and metabolic syndrome: new therapeutic approaches. Nutrition 2008;24:820-6
276. Han SH, Sakuma I, Shin EK, Koh KK. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis 2009;52:126-40
277. Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond) 2008;32(Suppl 7):S13-18
278. Yada T, Dezaki K, Sone H, et al. Ghrelin regulates insulin release and glycemia: physiological role and therapeuticpotential. Curr Diabetes Rev 2008;4:18-23 (Pubitemid 351210968)
279. Herzog H. Neuropeptide Y and energy homeostasis: insights from Y receptor knockout models. Eur J Pharmacol 2003;480:21-9 (Pubitemid 37410358)
280. Winzell MS, Ahren B. G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes. Pharmacol Ther 2007;116:437-48 (Pubitemid 350116941)
281. Lin S, Boey D, Herzog H. NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides 2004;38:189-200 (Pubitemid 39161911)